IL166331A0 - 5-arylterazole compounds compositions thereof and uses therefor - Google Patents

5-arylterazole compounds compositions thereof and uses therefor

Info

Publication number
IL166331A0
IL166331A0 IL16633105A IL16633105A IL166331A0 IL 166331 A0 IL166331 A0 IL 166331A0 IL 16633105 A IL16633105 A IL 16633105A IL 16633105 A IL16633105 A IL 16633105A IL 166331 A0 IL166331 A0 IL 166331A0
Authority
IL
Israel
Prior art keywords
arylterazole
uses therefor
compounds compositions
compositions
compounds
Prior art date
Application number
IL16633105A
Other languages
English (en)
Original Assignee
Inotek Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inotek Pharmaceuticals Corp filed Critical Inotek Pharmaceuticals Corp
Publication of IL166331A0 publication Critical patent/IL166331A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL16633105A 2002-07-18 2005-01-17 5-arylterazole compounds compositions thereof and uses therefor IL166331A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/197,609 US7078423B2 (en) 2002-07-18 2002-07-18 5-Aryltetrazole compounds, compositions thereof, and uses therefor
PCT/US2003/022462 WO2004009563A1 (en) 2002-07-18 2003-07-17 5-aryltetrazole compounds, compositions thereof, and uses therefor

Publications (1)

Publication Number Publication Date
IL166331A0 true IL166331A0 (en) 2006-01-16

Family

ID=30769479

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16633105A IL166331A0 (en) 2002-07-18 2005-01-17 5-arylterazole compounds compositions thereof and uses therefor

Country Status (16)

Country Link
US (1) US7078423B2 (xx)
EP (1) EP1542980A1 (xx)
JP (1) JP2005535678A (xx)
KR (1) KR20050028038A (xx)
CN (1) CN1694875A (xx)
AU (1) AU2003249313A1 (xx)
BR (1) BR0312768A (xx)
CA (1) CA2492847A1 (xx)
HU (1) HUP0500871A3 (xx)
IL (1) IL166331A0 (xx)
MX (1) MXPA05000765A (xx)
NZ (1) NZ538313A (xx)
PL (1) PL374833A1 (xx)
RU (1) RU2005104429A (xx)
WO (1) WO2004009563A1 (xx)
ZA (1) ZA200501431B (xx)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7087631B2 (en) * 2002-07-18 2006-08-08 Inotek Pharmaceuticals Corporation Aryltetrazole compounds, and compositions thereof
PA8578101A1 (es) * 2002-08-13 2004-05-07 Warner Lambert Co Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
US7037927B2 (en) * 2003-10-16 2006-05-02 Abbott Laboratories Amides that inhibit vanilloid receptor subtype 1 (VR1) receptor
WO2006121995A2 (en) 2005-05-09 2006-11-16 Tap Pharmaceutical Products, Inc. Methods for treating nephrolithiasis
BRPI0714315B8 (pt) * 2006-06-29 2021-05-25 Hoffmann La Roche arilamidas substituídas com tetrazol, seu uso e composição farmacêutica que as compreende
BRPI0718611A2 (pt) * 2006-11-13 2014-02-25 Takeda Pharmaceuticals North America Inc Métodos para preservar a função renal utilizando inibidores da xantina oxidoredutase.
EP2120956A4 (en) * 2007-01-19 2010-01-20 Takeda Pharmaceuticals North A METHODS FOR PREVENTING OR REDUCING THE NUMBER OF DROUGHT ERYTHEMES USING XANTHINE OXYDOREDUCTASE INHIBITORS AND INFLAMMATORY AGENTS
MX2009010491A (es) * 2007-04-11 2009-11-09 Kissei Pharmaceutical Derivado heterociclico de 5 miembros y su uso para propositos medicos.
CA2701214C (en) * 2007-10-04 2016-08-02 F. Hoffmann-La Roche Ag Tetrazole-substituted aryl amide derivatives and uses thereof
EP2282736B1 (en) * 2008-04-30 2015-11-11 Wellstat Therapeutics Corporation Tetrazole compounds for reducing uric acid
EP2480531B1 (en) 2009-09-21 2014-11-05 ChemoCentryx, Inc. Pyrrolidinone carboxamide derivatives as chemerin-r (chemr23) modulators
WO2011046800A1 (en) * 2009-10-13 2011-04-21 Wellstat Therapeutics Corporation 3-substituted compounds for reducing uric acid
US9918964B2 (en) * 2010-04-23 2018-03-20 The Board Of Trustees Of The Leland Stanford Junior University Reducing platelet activation, aggregation and platelet-stimulated thrombosis or blood coagulation by reducing mitochondrial respiration
KR101797936B1 (ko) 2010-09-10 2017-11-15 다케다 파마슈티칼스 유에스에이, 인코포레이티드 테오필린과 페북소스타트의 병용 치료 방법
WO2014079850A1 (en) * 2012-11-23 2014-05-30 F. Hoffmann-La Roche Ag Substituted heterocyclic derivatives
WO2016187521A1 (en) * 2015-05-21 2016-11-24 South Connecticut State University 5-substituted 1 h-tetrazole compounds, methods of synthesizing and therapeutic use
WO2019132782A1 (en) * 2017-12-29 2019-07-04 Agency For Science, Technology And Research Compounds for treating eye diseases and methods thereof
CN114466847A (zh) * 2019-06-25 2022-05-10 西诺普塞疗法公司 用于治疗癌症的化合物
CN112047896B (zh) * 2020-10-12 2022-06-17 上海麦克林生化科技有限公司 芳环基或芳杂环基四氮唑的合成方法
CN114805233A (zh) * 2022-03-30 2022-07-29 华南理工大学 苯基四氮唑类xor抑制剂及其制备方法与应用
CN115717258A (zh) * 2022-12-09 2023-02-28 上海天承化学有限公司 一种用于印制线路板脉冲填孔电镀的整平剂及其应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5049572A (en) * 1987-04-06 1991-09-17 Riker Laboratories, Inc. Substituted di-t-butylphenols and anti-allergic use thereof
IT1232252B (it) 1989-02-22 1992-01-28 Rotta Research Lab Derivati della n fenil benzamide ad attivita' antiulcera ed antiallerica e procedimento per la loro preparazione
US5284954A (en) 1990-09-10 1994-02-08 Abbott Laboratories Process for the preparation of tetrazoles
IT1256870B (it) 1992-02-13 1995-12-27 Rotta Research Lab Derivati bis-tetrazolici ad attivita' antiallergica e citoprotettiva
US5364869A (en) 1992-03-09 1994-11-15 Abbott Laboratories Heterocycle-substituted benzyaminopyridine angiotensin II receptor antagonists
DE4326344A1 (de) 1993-08-05 1995-02-09 Thomae Gmbh Dr K Carbonamide, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE69531435T2 (de) 1994-05-16 2004-07-01 Sumitomo Chemical Co., Ltd. Verfahren zur herstellung von tetrazolverbindungen
US5663357A (en) 1995-11-22 1997-09-02 Allergan Substituted heteroarylamides having retinoid-like biological activity
JPH1025294A (ja) 1996-03-26 1998-01-27 Akira Matsuda 縮合ヘテロ環誘導体、その製造法及びそれを含有する悪性腫瘍治療剤
WO1997045400A1 (en) 1996-05-24 1997-12-04 Neurosearch A/S Phenyl derivatives containing an acidic group, their preparation and their use as chloride channel blockers
US6696475B2 (en) 1997-04-22 2004-02-24 Neurosearch A/S Substituted phenyl derivatives, their preparation and use
BR9808938A (pt) 1997-04-22 2000-08-01 Neurosearch As Composto, composição farmacêutica, uso de um composto, processos para o tratamento de um distúrbio ou doença de um corpo de animal vivo e para a preparação de um composto, e, uso de bloqueadores de canal de cloreto
AU735233B2 (en) 1997-06-19 2001-07-05 British Telecommunications Public Limited Company Sound reproduction system
PT896821E (pt) 1997-08-08 2003-08-29 Rotta Research Lab Uma nova composicao farmaceutica para inalacao que contem cr 2039 (andolast)
EP1044002A4 (en) 1997-11-07 2003-05-02 Univ Johns Hopkins METHODS FOR THE TREATMENT OF HEART CONTRACTILITY
EP1030853A1 (en) 1997-11-12 2000-08-30 Ariad Pharmaceuticals, Inc. Novel signal transduction inhibitors, compositions containing them
AUPP609198A0 (en) 1998-09-22 1998-10-15 Curtin University Of Technology Use of non-peptidyl compounds for the treatment of insulin related ailments
ATE286021T1 (de) 1998-10-22 2005-01-15 Neurosearch As Substituierte phenylderivate, ihre herstellung und verwendung
EP1131059B1 (de) 1998-11-13 2003-03-05 Jago Research Ag Trockenpulver zur inhalation
ES2287016T3 (es) 1999-04-28 2007-12-16 Sanofi-Aventis Deutschland Gmbh Derivados de diaril-acido como ligandos del receptor ppar.
US6281222B1 (en) 1999-08-19 2001-08-28 Inotek Corporation Compositions and method for treatment of acetaminophen intoxication
IL151517A0 (en) 2000-03-09 2003-04-10 Aventis Pharma Gmbh Therapeutic uses of ppar mediators
DE10023430A1 (de) 2000-05-12 2001-11-15 Bayer Ag Substituierte N-Benzoyl-N'-(tetrazolylphenyl)-harnstoffe
US6599926B2 (en) 2000-06-23 2003-07-29 Bristol-Myers Squibb Company Heteroaryl-phenyl substituted factor Xa inhibitors
US6369232B1 (en) 2000-08-15 2002-04-09 Hoffmann-La Roche Inc. Tetrazolyl-phenyl acetamide glucokinase activators
ES2288195T3 (es) 2001-09-14 2008-01-01 Novo Nordisk A/S Nuevos ligandos para sitios hisb10 zn2+ del hexamero de insulina en la configuracion r.

Also Published As

Publication number Publication date
CA2492847A1 (en) 2004-01-29
CN1694875A (zh) 2005-11-09
US7078423B2 (en) 2006-07-18
US20040019208A1 (en) 2004-01-29
WO2004009563A1 (en) 2004-01-29
EP1542980A1 (en) 2005-06-22
NZ538313A (en) 2005-09-30
JP2005535678A (ja) 2005-11-24
BR0312768A (pt) 2005-05-10
PL374833A1 (en) 2005-10-31
HUP0500871A2 (hu) 2005-12-28
KR20050028038A (ko) 2005-03-21
ZA200501431B (en) 2006-02-22
RU2005104429A (ru) 2005-08-27
HUP0500871A3 (en) 2006-11-28
MXPA05000765A (es) 2005-10-19
AU2003249313A1 (en) 2004-02-09

Similar Documents

Publication Publication Date Title
IL166331A0 (en) 5-arylterazole compounds compositions thereof and uses therefor
GB0220467D0 (en) Composition
GB0213638D0 (en) Composition
GB0212062D0 (en) Jetable compositions
GB0224415D0 (en) Compositions
GB0229742D0 (en) Novel compounds and uses thereof
AU2003256805A8 (en) Compounds compositions and methods
GB0318894D0 (en) Composition
GB0208609D0 (en) Compositions
GB0203421D0 (en) Composition
GB0227244D0 (en) Composition
GB0208608D0 (en) Composition
GB0221894D0 (en) Compositions
GB0203280D0 (en) Anti-glycolytic composition
AU2003269904A8 (en) Antigen-polymer compositions
GB0203395D0 (en) Compositions
GB0211924D0 (en) Composition
GB0218241D0 (en) Composition
GB0318152D0 (en) Composition
GB0203396D0 (en) Compositions
HK1082517A1 (en) Oil-barrier composition
GB0217366D0 (en) Compositions
EP1495751A4 (en) hair dye
GB0207224D0 (en) Tenascin-W compositions and uses thereof
GB0211949D0 (en) Novel compounds compositions and processes